Adcock Ingram Holdings Limited

Who owns Adcock Ingram?
The Bidvest Group is the controlling shareholder, with India's NATCO Pharma holding 35.75% since November 2025. The company delisted from the JSE on 11 November 2025.

Is Adcock Ingram still listed on the JSE?
No. Adcock Ingram Holdings delisted on 11 November 2025 after NATCO Pharma acquired the minority shares at R75 per share in a transaction valued at about ZAR 4 billion.

When was Adcock Ingram founded?
The company's roots trace to E.J. Adcock's pharmacy in Krugersdorp in 1891, making it one of South Africa's oldest pharmaceutical businesses.

What brands does Adcock Ingram make?
Its best-known brands include Panado, Myprodol, Epi-Max, Citro-Soda, Allergex, Corenza C, Alcophyllex and Bioplus, plus extensive prescription and hospital product lines.

Where is Adcock Ingram headquartered?
The company is headquartered in Midrand, Gauteng, South Africa, with manufacturing facilities including its Wadeville plant and interests in India.

Why did NATCO Pharma invest in Adcock Ingram?
NATCO described the 35.75% acquisition as its entry into the South African market, gaining an established manufacturing base, distribution network and trusted local brands.

The company's lineage begins in 1891, when E.J. Adcock opened a pharmacy in Krugersdorp in the South African Republic. The Ingram side traces to a parallel Johannesburg pharmacy business; the two pharmaceutical houses merged over the twentieth century into the entity known as Adcock Ingram.

The modern structure emerged in the 1950s when the company began manufacturing branded generics and consumer healthcare products, building a portfolio anchored by analgesics Panado and Myprodol. Tiger Brands acquired control in the 1970s, running Adcock as its healthcare arm for three decades.

In 2008 Tiger Brands unbundled Adcock Ingram and listed it separately on the JSE. The Bidvest Group, the industrial conglomerate run by Brian Joffe, progressively built its stake and by the mid-2010s held effective control, later formalized around 63%.

Strategic moves under Bidvest included expanding OTC and consumer lines, acquiring personal care brands, and building Indian manufacturing interests. A proposed acquisition of smaller rival Cipla Medpro was explored, and the group periodically weighed consolidation in the concentrated South African pharma market. Its largest attempted deal, a 2024-era tilt at peer expansion, did not materialize, and FY2025 results were flat: revenue of R9.76 billion, up 1%, with trading profit of R1.18 billion.

The decisive event was the July 2025 announcement that NATCO Pharma, an Indian generics multinational, would acquire all Adcock shares not held by Bidvest at R75 per share through a scheme of arrangement. Shareholders approved in October 2025 and the company delisted from the JSE on 11 November 2025, ending 17 years as a listed entity. NATCO framed the stake as its entry into the South African market, while Bidvest retained control.

Adcock Ingram's record includes industry-standard regulatory exposure: product recalls executed at manufacturer level over the years, Medicines Control Council/SAHPRA oversight, and periodic pricing regulation debates. No major fraud or sanction defines its public history. The 2025 delisting itself drew scrutiny over minority exit pricing, though shareholders approved the R75 scheme overwhelmingly.